Context Therapeutics Secures FDA Fast Track For CTIM-76 In Ovarian Cancer, Advancing Novel Bispecific Antibody Development

Context Therapeutics Inc. announced that the U.S. Food and Drug Administration has granted Fast Track Designation to CTIM-76, a bispecific antibody targeting CLDN6 and CD3, for the treatment of platinum-resistant ovarian cancer in patients who have exhausted standard therapies.

CTIM-76 is currently being evaluated in a Phase 1 clinical trial involving patients with CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancers. The study is assessing safety, tolerability, pharmacokinetics, and early signs of anti-tumour activity, including response rates and disease control outcomes.

“We are pleased to receive Fast Track Designation for CTIM-76, which underscores its potential to improve the lives of patients with platinum-resistant ovarian cancer,” said Karen Chagin, M.D., Chief Medical Officer of Context. “This designation is an important step forward in our goal to quickly and efficiently advance CTIM-76 through clinical development and we look forward to sharing interim data for this program in June 2026.”

The Fast Track designation is intended to accelerate the development and regulatory review of therapies that address serious conditions with unmet medical needs, potentially enabling faster access to innovative treatments for patients.